BioSpace News Archive

MaxCyte announced today that the first patient has been dosed in its Phase I dose-escalation clinical trial in the United States with the Company’s lead wholly-owned chimeric antigen receptor (CAR) therapeutic candidate, MCY-M11.

Bristol-Myers Squibb’s blockbuster checkpoint inhibitor Opdivo failed to meet endpoints as a treatment option for small cell lung cancer (SCLC) patients who relapsed following platinum-based chemotherapy.

Rewind Therapeutics today announces the establishment of a Scientific Advisory Board (SAB) composed of eminent scientists in the fields of multiple sclerosis, myelination and neuroscience drug discovery and development.

Produced from renewable materials, Minasolve’s new fragrance agent and skin moisturizer are innovative alternatives for preserving the quality of cosmetic products

Exclusively licensed, rhabdovirus-free platform enables more productive bioprocessing

UH Biologist Discovers Protein Partnership That Protects Blood Vessels

For those looking for work, it’s good to know that some positions are in such demand that employers are falling all over themselves to offer hiring incentives. That’s the case with the biotech sector in Massachusetts, as many companies are dangling almost unheard-of benefits as incentives.

Things seem to have gone from bad to worse for Pennsylvania-based Trevena, Inc. This week the company saw a U.S. Food and Drug Administration advisory committee reject its intravenous pain treatment and now a class action lawsuit filed against the company claims Trevena executives have misled investors for years.

Forbes came out with its ranking of the World’s Best Employers 2018, with a number of global biopharmaceutical companies ranked high on the list. Here’s the top 10 in that category.

Researchers at Johns Hopkins, the University of California, San Diego, and the National Institute of Mental Health grew retinas in petri dishes, and discovered fundamental factors involved in the development of vision and color vision.